In silico characterization of Echinococcus granulosus paramyosin nucleotide sequence for the development of epitope vaccine against cystic echinococcosis
Author:
Lu Y.-J.12, Chen D.-Sh.12, Hao W.-T.1, Xu H.-W.12, Zhang Y.-W.12, Sun F.-F.1, Pan W.1
Affiliation:
1. Jiangsu Key Laboratory of Immunity and Metabolism , Department of Pathogenic Biology and Immunology, Laboratory of Infection and Immunity , Xuzhou Medical University , 209 Tongshan Road, Xuzhou 221004 , Jiangsu Province, China 2. Department of Clinical Medicine , Xuzhou Medical University , 209 Tongshan Road, Xuzhou 221004 , Jiangsu Province, China
Abstract
Summary
The paramyosin (Pmy) protein has been presented as a potential vaccine candidate against Schistosoma spp. However, it remains elusive whether it works in controlling cystic echinococcosis (CE), which is caused by the larval stages of Echinococcus granulosus (E. granulosus). This study investigated the characteristics of E. granulosus Pmy (EgPmy) using in silico analysis and evaluated its potential as an epitope vaccine. The secondary structure was predicted by SOPMA software and linear B-cell epitopes were screened by the Kolaskar and Tongaonkar’s method on IEBD while conformational B-cell epitopes were predicted by the Ellipro. Additionally, the epitopes of cytotoxic T lymphocyte (CTL) were analyzed by the NetCTL-1.2 server. The results showed that α-helices, extended strands, random coils and β-turns accounted for 84.82 %, 6.60 %, 5.56 % and 3.01 % in EgPmy’s secondary structure, respectively. A total of 29 linear B-cell epitopes and 6 conformational epitopes were identified together with 25 CTL epitopes. The CTL epitope 709KLEEAEAFA717 showed a high potential to elicit CTL response. These results suggested that EgPmy has a strong immunogenicity, which could serve as a reference for the development of EgPmy-based epitope vaccine against CE.
Publisher
Walter de Gruyter GmbH
Subject
Animal Science and Zoology,Parasitology
Reference39 articles.
1. Ben, Y.T., Arnon, R. (2005): Towards an epitope-based human vaccine for influenza. Hum. Vaccin., 1(3): 95 – 101 2. Calis, J.J., Maybeno, M., Greenbaum, J.A., Weiskopf, D., De-Silva, A.D., Sette, A., Kesmir, C., Peters, B. (2013): Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput. Biol., 9(10): e1003266. DOI: 10.1371/journal.pcbi.1003266 3. Cohen, C. (1982): Matching molecules in the catch mechanism. Proc. Natl. Acad. Sci. USA, 79: 3176 – 317810.1073/pnas.79.10.3176 4. Eckert, J., Conraths, F.J., Tackmann, K. (2000): Echinococcosis: an emerging or re-emerging zoonosis? Int. J. Parasitol., 30(12 – 13): 1283 – 129410.1016/S0020-7519(00)00130-2 5. Emini, E.A., Hughes, J.V., Perlow, D.S., Boger, J. (1985): Induction of hepatitis A virus-neutralizing antibo dy by a virus-specific synthetic peptide. J. Virol., 55(3): 836–839.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|